#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pneumonia Cardiomyopathy Bladder cancer Phaeochromocytoma Subdural haematoma Chronic lymphocytic leukaemia recurrent Lymphatic malformation Hypocalcaemia Myasthenia gravis Ichthyosis Erdheim-Chester disease Type IIa hyperlipidaemia Hyperinsulinism Paraneoplastic neurological syndrome Oropharyngeal squamous cell carcinoma More trials…

    Learn about Rare Diseases

    Acute respiratory distress syndrome – Life with Disease Undifferentiated sarcoma Hereditary motor and sensory neuropathy Mastocytosis – Diagnostics Small intestine leiomyosarcoma – Basic Information KBG syndrome – Life with Disease Myxofibrosarcoma Haemophilia B with anti factor IX – Treatment Mucopolysaccharidosis III – Diagnostics Waldenstrom’s macroglobulinaemia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Estradiol Cortisone Mosaic Hbcoreag Hydroxychloroquine Sulfate Lolium Perenne Bupivacaine Vgl101 ALE1 Omx-0407 Beclometasone Dipropionate Sot102 Emraclidine TIL CELLS Ng004 Amlodipine Besilate Adrc001 Wt1/Il15/Il15Ra Mrna Dc Mebeverine Hydrochloride Doxecitine Celecoxib More therapies…

    Learn about Your Condition

    Basal cell carcinoma Spinal muscular atrophy Oesophageal adenocarcinoma Deafness neurosensory Macular oedema Ankylosing spondylitis Bone marrow disorder Breast cancer recurrent Patent ductus arteriosus Kaposi's sarcoma Adenocarcinoma pancreas Congenital ureteric anomaly Brain neoplasm Pseudomonas infection Lymphocytic lymphoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nervous System Diseases

  • Study on the Effects of Annual vs. Semi-Annual Ocrelizumab Infusions in Patients with Active Multiple Sclerosis After 2 Years of Initial Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    France

  • Study on the Safety and Effectiveness of Atogepant for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

    Recruiting

    3 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Atogepant
    Belgium Denmark France Hungary Italy The Netherlands +4

  • Study on the Effectiveness of Botulinum Toxin A and Sodium Chloride for Patients with Trigeminal Neuralgia

    Recruiting

    3 1 1
    Investigated Diseases:
    • Trigeminal neuralgia
    Investigated Drugs:
    • Botulinum Toxin Type A
    • Sodium Chloride
    Denmark

  • Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

    Recruiting

    3 1 1
    Investigated Drugs:
    • Atogepant
    Belgium Denmark France Hungary Italy The Netherlands +5

  • Study on Neurodegenerative Diseases Using [18F]RO6958948 for Early Detection and Mapping in At-Risk Patients

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neurodegenerative disorder
    Investigated Drugs:
    • 2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3′,4′-D]Pyrrole
    Sweden

  • Comparison of ocrelizumab and rituximab treatment in adults with active relapsing-remitting multiple sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    • Rituximab
    Norway Sweden
Previous Page
1 … 52 53 54 55 56 … 141
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!